Remove Licensing Remove Production Remove Protein
article thumbnail

Dyadic expands Covid-19 licence with Rubic to bolster vaccine production in Africa

Pharmaceutical Technology

Dyadic International has announced expansion of a licence agreement for its C1-cell protein expression platform with South African consortium Rubic One Health. The expanded licence will include the development of vaccines and therapeutic proteins beyond Covid-19 for human and animal health markets in Africa.

article thumbnail

Kite and Daiichi Sankyo update cell therapy licensing agreement

Pharmaceutical Technology

The delivery of the product is anticipated to begin early next year. Directed against a cell membrane protein called CD19, Yescarta uses the immune system of the patient to destroy cancer. The post Kite and Daiichi Sankyo update cell therapy licensing agreement appeared first on Pharmaceutical Technology.

Licensing 305
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Gilead Sciences to exclusively license Nurix Therapeutics’ protein degrader

Pharmaceutical Technology

Gilead Sciences has exercised its option to exclusively license the investigational targeted protein degrader development candidate, NX‑0479, from clinical-stage biopharmaceutical company Nurix Therapeutics. Additionally, Nurix will receive up to low double-digit tiered royalties on the net sales of the product.

Protein 130
article thumbnail

Astellas and Cullgen to develop small molecule protein degraders

Pharmaceutical Technology

Japan-based Astellas Pharma has entered a partnership with Cullgen to discover and develop multiple targeted protein degraders through the latter’s proprietary uSMITE targeted protein degradation platform, in a deal potentially worth $1.9bn. Astellas could pay Cullgen up to $85m upon using its license option regarding the deal.

Protein 130
article thumbnail

Twist Bioscience and Astellas team up for antibody discovery

Pharmaceutical Technology

Astellas will license a suite of single-domain antibody (VHH) libraries from Twist for five years to conduct research and development activities. The company is also expected to receive royalty payments on sales of the product. This will create high-quality VHH libraries for use against any target protein.

Antibody 264
article thumbnail

Sourcing Blockbuster Oncology Products for Clinical Trial Supply

XTalks

Oncology products monopolise the list of best-selling drugs. Several oncology products now have “blockbuster” status where sales exceed $1 billion annually. This is relevant for clinical trials as more regulators require evidence of efficacy in comparison to the standard of care, which is likely to be one of the blockbuster products.

article thumbnail

CSL doses first patient with haemophilia B gene therapy Hemgenix

Pharmaceutical Technology

In the past year, Hemgenix has been granted approval by the US Food and Drug Administration (FDA) and has received conditional marketing authorisation from the European Commission (EC) and the UK’s Medicines and Healthcare products Regulatory Agency (MHRA). This followed positive results from CSL’s Phase III HOPE-B trial (NCT03569891).